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Circulating tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) levels are reduced in
patientswith cardiovascular disease, and TRAIL gene deletion inmice exacerbates atherosclerosis and
inflammation. How TRAIL protects against atherosclerosis and why levels are reduced in disease is
unknown. Here, multiple strategies were used to identify the protective source of TRAIL and its mech-
anism(s) of action. Samples from patients with coronary artery disease and bone-marrow transplanta-
tion experiments in mice lacking TRAIL revealed monocytes/macrophages as the main protective
source. Accordingly, deletion of TRAIL caused a more inflammatory macrophage with reduced migra-
tion, displaying impaired reverse cholesterol efflux and efferocytosis. Furthermore, interleukin
(IL)-18, commonly increased in plasma of patients with cardiovascular disease, negatively regulated
TRAIL transcription and gene expression, revealing an IL-18-TRAIL axis. These findings demonstrate
that TRAIL is protective of atherosclerosis bymodulatingmonocyte/macrophage phenotype and func-
tion. Manipulating TRAIL levels in these cells highlights a different therapeutic avenue in the treat-
ment of cardiovascular disease.
INTRODUCTION
Despite improvements in treatment, cardiovascular disease (CVD) remains the leading cause of death
worldwide. The main cause is atherosclerosis, the pathological process underlying stroke, coronary artery
disease (CAD), and peripheral vascular disease. Cells of the myeloid lineage, particularly monocyte/mac-
rophages, play a pivotal role in atherogenesis, which is triggered by an inflammatory response to lipopro-
teins that are modified in the vessel wall. Here, innate responses initiate the recruitment, homing, migra-
tion, and differentiation of monocytes into macrophages, where they orchestrate a plethora of functions
including phagocytosis, efferocytosis, proliferation, migration, secretion of inflammatory molecules (e.g.,
tumor necrosis factor alpha [TNF-a]), production of resolving molecules (e.g., interleukin [IL]-10), and
cell death. In mature lesions, failure of macrophage resolution mechanisms and the subsequent increased
immune response may underlie processes that exacerbate disease (Tabas, 2010).
TNF-related apoptosis-inducing ligand (TRAIL) was originally identified as a cancer-killing cytokine, but
over the last 10 years it has become clear that TRAIL has pleiotropic functions beyond killing and canmodu-
late multiple cellular processes, including proliferation, migration, and differentiation (Harith et al., 2013;
Kavurma and Bennett, 2008; Kavurma et al., 2008b; Manuneedhi Cholan et al., 2017). Our particular interest
is its role in CVD. In humans, low plasma TRAIL levels independently predict cardiovascular events andmor-
tality (Volpato et al., 2011), and TRAIL is reduced in the circulation of patients with CVD (Schoppet et al.,
2006), suggesting a protective role. The recent identification of 11 loss-of-function TRAIL single-nucleotide
polymorphisms (SNPs) that confer increased risk of carotid artery atherosclerosis supports this view (Pott
et al., 2017). We and others identified TRAIL’s non-apoptotic functions in the vasculature, including in neo-
intimal thickening, angiogenesis, and peripheral vascular disease, and in advanced atherosclerosis (Chan
et al., 2010; Di Bartolo et al., 2011, 2013, 2015; Kavurma et al., 2008a; Secchiero et al., 2004a, 2006). Our
atherosclerotic murine models lacking TRAIL corroborate the human association studies. For example,
high-fat diet (HFD)-fed Trail/Apoe/mice exhibited 150% larger plaques thanApoe/mice (Di Bartolo
et al., 2011). Intriguingly, these mice not only had significantly more monocyte/macrophages in theiriScience 12, 41–52, February 22, 2019 ª 2019 The Authors.
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Figure 1. Circulating TRAIL Is Reduced in Patients with CAD, Associating with Reduced Monocyte TRAIL mRNA
(A–C) Blood from the coronary sinus, aortic root (arterial), and lower right atrium (venous) were collected and assayed for (A) TRAIL and (B) TNF-a by ELISA.
(C) The coronary sinus-arterial TRAIL gradient. Patient samples are n = 8–15/group.
(D and E) Venous blood was collected from healthy controls (n = 7) and a second cohort of patients with CAD (n = 11) and assayed for (D) plasma TRAIL and (E)
monocyte TRAIL gene expression by qPCR. mRNA expression was normalized to GAPDH.
Results are mean G SEM. One-way ANOVA or t-test; *p < 0.05, **p < 0.01, ***p < 0.001.plaques but also increasedmonocyte/macrophage numbers in kidney (Cartland et al., 2014) and pancreata
(Di Bartolo et al., 2011), suggesting that TRAIL may control macrophage accumulation in injured tissues. In
contrast to our observations, TRAIL administration to diabetic Apoe/mice attenuated atherosclerosis, in
part, by inducing macrophage death (Secchiero et al., 2006). Thus, the role of TRAIL in monocyte/macro-
phage function is unclear. Here we examined samples from patients with CAD and several murine models
of atherosclerosis, as well as monocyte/macrophages in vitro. We identified an iNOShiTRAIL+ macrophage
population that appeared critical in resolving atherosclerosis. Furthermore, we describe a unique anti-in-
flammatory pathway, the IL-18-TRAIL axis, in patients with CAD. These findings suggest that TRAIL is critical
in modulating atherogenesis and has wider implications in mechanisms regulating inflammation.RESULTS
Circulating TRAIL Is Reduced in Patients with CAD and Associates with Reduced Monocyte
TRAIL mRNA
To assess local coronary production of TRAIL, we measured plasma concentrations in blood sampled from
three sites around the heart, collected from control subjects and stable and unstable patients with CAD.
Regardless of sampling site, TRAIL was significantly lower in plasma from patients with CAD, 45% less
than control levels (Figure 1A). In contrast, TNF-a (Figure 1B), a cytokine with high sequence homology
to TRAIL, was similar in all samples. No differences were found in the TRAIL arterial-coronary sinus gradient
(Figure 1C), indicating that the source of TRAIL was systemic rather than directly from the heart. Plasma
from a second cohort of patients with unstable CAD also contained markedly less TRAIL at 70% less
than control levels (Figure 1D). TRAIL mRNA in monocytes from the same individuals was also strikingly
reduced (70%; Figure 1E), implicating these cells as a major source of TRAIL in healthy circulation, which
may be compromised in patients with CAD.TRAIL Expressing Monocyte/Macrophages Protect against Atherosclerosis
Wildtype mice do not develop significant atherosclerosis without the disruption of genes critical in choles-
terol metabolism. Apolipoprotein E (ApoE) is key in maintaining plasma cholesterol concentrations. Dele-
tion inmice causes hypercholesterolemia and spontaneous development of atherosclerotic lesions that are
accelerated by HFD feeding (Meir and Leitersdorf, 2004). We showed that TRAIL deletion in Apoe/mice
(Trail/Apoe/) exacerbated plasma cholesterol levels, and macrophage-rich plaques were larger and42 iScience 12, 41–52, February 22, 2019
Figure 2. BM-TRAIL Attenuates Atherosclerosis
(A) BMT study design.
(B) Atherosclerosis is reduced in BM-TRAIL vs. null- or parenchymal-TRAIL treatment groups. Left, representative H&E brachiocephalic arteries. Right,
quantification of plaque area (n = 5–8/group; scale bar, 20 mm).
(C) Progression of atherosclerosis in Trail/Apoe/ mice in response to an HFD over 12 weeks. Left, representative H&E brachiocephalic arteries. Right,
quantification of plaque area (n = 3–4/group).
(D) Atherosclerosis was reduced in HFD Trail/Apoe/mice treated with clodronate liposomes. Left, representative H&E brachiocephalic arteries. Right,
quantification of plaque area (n = 5–7/group; scale bar, 20 mm).
(E) BM-TRAIL reduces Mac3+ staining in plaque. Left, Mac3+ staining. Right, quantification of staining (n = 5–8/group; scale bar, 20 mm).
(F) Aortic TRAIL mRNA expression in BMT mice by qPCR (n = 5–8/group).
Results are mean G SEM. One-way ANOVA or Mann-Whitney U-test; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.more frequent than in Apoe/mice fed a HFD (Di Bartolo et al., 2011). These findings indicated a protec-
tive role for TRAIL.
Monocytes originate in bone marrow, and because they were a significant source of TRAIL in people (Fig-
ure 1), we predicted that TRAIL-expressing (TRAIL+) bone marrow afforded protection in atherosclerosis.
To investigate this, we examined two sources using bone marrow chimeras: TRAIL expressed only in the
bone marrow (BM-TRAIL) and TRAIL expressed everywhere except the bone marrow (parenchymal-TRAIL).
Results were compared with mice with no TRAIL in bone marrow or parenchyma (null-TRAIL). The bone
marrow chimera study design is illustrated in Figure 2A. Brachiocephalic arteries of BM-TRAIL mice had
significantly reduced atherosclerotic lesion size compared with the null- and parenchymal-TRAIL lesions,
which had 50% more atherosclerosis (Figure 2B). Body weight and plasma chemistries, including total
cholesterol, triglycerides, glucose and insulin were similar between groups (Table 1). Interestingly, athero-
sclerotic lesions from BM-TRAIL mice were of similar size to those in Trail/Apoe/ samples harvested
after only 5–8 weeks HFD (Figure 2C), suggesting that TRAIL expressed in the bone marrow slows athero-
genesis. Depletion of macrophages in HFD-fed Trail/Apoe/ using clodronate liposomes dramatically
reduced atherosclerotic plaque size (Figure 2D), confirming that a significant number of cells in the plaque
are of monocyte/macrophage origin. Immunohistochemical assessment showed significantly lower
numbers of Mac3+ macrophages in BM-TRAIL plaque compared with those in lesions from null- or paren-
chymal-TRAIL mice (Figure 2E). Furthermore, TRAIL mRNA expression from BM-TRAIL aortae was50-foldiScience 12, 41–52, February 22, 2019 43
Null BM Parenchymal
Body weight (g) 28.38G 1.9 27.20G 0.8 28.17G 0.7
Glucose (mmol/L) 7.58G 0.8 7.16G 0.6 8.98G 0.3
Insulin (pmol/L) 44.87G 3.2 37.73G 2.1 40.75G 2.8
Cholesterol (mmol/L) 18.04G 3.3 19.28G 2.4 21.95G 5.9
Triglycerides (mmol/L) 2.29G 0.3 1.99G 0.3 1.96G 0.5
TRAIL (pg/mL) 0 810.7G 108.2 1966G 503.5*
Table 1. Body Weight and Plasma Chemistries from Bone Marrow Chimera Mice
Body weight and plasma chemistries from null-, BM, and parenchymal-TRAIL mice at euthanasia (n = 5–8/group). Results are
meanG SEM. One-way ANOVA; *p < 0.05 vs. BM.less than parenchymal-TRAIL samples (Figure 2F) reinforcing the profound effect of TRAIL+monocyte/mac-
rophages in reducing lesion size (Figure 2B); TRAIL was undetectable in aortae from null-TRAIL mice (Fig-
ure 2F). In agreement with this, plasma from BM-TRAIL mice had significantly reduced TRAIL concentra-
tions, 2.5-fold less than in plasma from parenchymal-TRAIL mice (Table 1). By combining plasma TRAIL
concentrations from BM-TRAIL and parenchymal-TRAIL mice (Table 1), we estimated that 30% of plasma
TRAIL was derived from cells originating in the bone marrow. Collectively, these findings indicate that BM
cells are a protective source of TRAIL and that TRAIL+ monocyte/macrophages markedly reduce
atherosclerosis.
To confirm that TRAIL+ monocyte/macrophages could also reduce inflammation and macrophage
numbers in other tissues, we examined pancreata from bone marrow chimera mice. There was 50%
less Mac3+ immunoreactivity in pancreata from BM-TRAIL mice compared with that in null-TRAIL pancre-
atic islets (Figure S1A). Macrophage accumulation was similarly reduced in parenchymal-TRAIL islets (Fig-
ure S1A). These indicate that TRAIL expression reduced monocyte/macrophage content regardless of its
source. However, although reconstitution with TRAIL+ monocyte/macrophages reduced atherosclerosis in
BM-TRAIL mice, this did not affect glucose handling. Glucose tolerance testing indicated that paren-
chymal-TRAIL mice had improved glucose clearance compared with null- or BM-TRAIL mice (Figure S1B)
associating with significantly reduced active caspase-3 staining (Figure S1C). Active caspase-3 immunore-
activity was also reduced in BM-TRAIL islets, although this did not reach significance (Figure S1C). No dif-
ferences in insulin tolerance, insulin expression, islet area, or islet number between groups were observed
(Figures S1D–S1G). These findings suggest that TRAIL+ monocyte/macrophages appear to have functions
distinct from TRAIL+ parenchymal cells, highlighting tissue- and cell-specific responses.Macrophages Lacking TRAIL Have Impaired Cholesterol Metabolism
Atherosclerosis associates with expanded hematopoietic stem cell numbers (Murphy et al., 2011). Because
HFD Trail/Apoe/ mice develop larger plaques than Apoe/ (Di Bartolo et al., 2011), and TRAIL+
monocyte/macrophage reconstitution attenuated atherosclerosis with concomitantly less macrophage
accumulation in vascular tissues (Figure 2), we assessed whether inherent differences in hematopoietic
stem cell numbers were associated with TRAIL deletion. No differences in hematopoietic stem cells, com-
mon myeloid, lymphoid, erythroid or granulocyte progenitors, or monocyte precursors in bone marrow
from Apoe/ (TRAIL+ve) vs. Trail/Apoe/ (TRAILve) mice were apparent (Figure S2), suggesting
that the changes we observed in Figure 2 occurred once the cells had left the bone marrow and
differentiated.
Cholesterol accumulation in macrophages is a defining feature of atherosclerosis (Jessup and Kritharides,
2008). Interestingly, TRAIL+ve macrophages loaded with acetlyated LDL (acLDL) had significantly reduced
TRAIL mRNA expression (Figure 3A). Macrophage cholesterol homeostasis is maintained by uptake and
export; cholesterol uptake can occur via scavenger receptors CD36 and SRA, and by phagocytosis of
aggregated LDL, whereas cholesterol export occurs primarily via reverse cholesterol transporters
ABCA1 and ABCG1 (Du et al., 2015; Out et al., 2008). We found that TRAILve (Trail/Apoe/) macro-
phages had no change in CD36 or SRA mRNA (Figure 3B) or phagocytic ability (Figure 3C). On the other44 iScience 12, 41–52, February 22, 2019
Figure 3. TRAIL Deletion Alters Cholesterol Metabolism in Macrophages
(A) TRAIL expression in TRAIL+ve macrophages in response to acLDL for 48 h followed by 16 h equilibration.
(B–D) (B) Scavenger receptor mRNA expression, (C) phagocytosis of beads, and (D) mRNA expression of cholesterol transporters ABCA1, ABCG1, and SRB1
in basal macrophages.
(E) Cholesterol efflux is impaired with TRAIL deletion, where cells were 3H-acLDL loaded for 48 h, followed by 16 h equilibration and efflux to ApoA1 for 4 h
(n = 3/group).
Results are mean G SEM. t-test; **p < 0.01 and ***p < 0.001.hand, ABCA1 and ABCG1 mRNA expression was significantly reduced (Figure 3D), and TRAILve macro-
phages had a diminished capacity to export cholesterol compared to TRAIL+ve macrophages, as evi-
denced by reduced cholesterol efflux to Apo-A1 (Figure 3E). These findings indicate that TRAIL deletion
in macrophages impairs reverse cholesterol transport, making macrophages more lipid laden.
Macrophages Lacking TRAIL Exacerbate Inflammation and Impair Efferocytosis
Activated monocyte/macrophages express and secrete inflammatory cytokines. The mechanisms by which
TRAIL may modulate inflammation in the vessel wall were analyzed, and the expression of inflammatory
cytokines involved in the progression of atherosclerosis wasmeasured. Consistent with accelerated athero-
sclerosis in mice with TRAIL deletion (Figures 2B and 2C), TRAILve macrophages had >2-fold higher
CCL-2 mRNA (Figure 4A), a potent monocyte chemoattractant implicated in atherosclerosis progression
(Aiello et al., 1999; Gu et al., 1998). TRAILve macrophages also had a more reactive, inflammatory pheno-
type following lipopolysaccharide (LPS) challenge, with significantly higher TNF-a, IL-1b, and IL-6 mRNA
expression than TRAIL+ve macrophages (Figure 4B). Correspondingly, anti-inflammatory IL-10 mRNA
was significantly reduced with TRAIL deletion (Figure 4B). Similarly, acLDL-loaded TRAILve macrophages
expressed more IL-1b and IL-6 but not TNFa (Figure 4C). CD11b expression is reduced on macrophages
involved in the resolution of inflammation (Ortega-Gomez et al., 2013). We showed that CD11b expression
on TRAILve macrophages was elevated, both at the level of mRNA and protein (Figures 4C and 4D).
Collectively, these findings imply that TRAIL deletion promotes an inflammatory macrophage.
Apoptosis is triggered by inflammation in atherosclerotic lesions, and macrophage apoptosis under these
circumstances can be detrimental if not coupled with effective efferocytosis (Kavurma et al., 2017). We next
examined cell viability, apoptosis, and expression of genes important in efferocytosis. Viability of TRAIL+ve
and TRAILve macrophages was similar (Figure 4F), and levels of apoptosis were low, with no difference
over 21 days in culture (Figure 4G). In contrast, MerTK mRNA was 50% less in TRAILve macrophages
(Figure 4H), associating with a significant reduction in efferocytosis (Figure 4I). Of note, MerTK is a trans-
membrane protein, mutation of which disrupts signaling, resulting in dysfunctional efferocytosis iniScience 12, 41–52, February 22, 2019 45
Figure 4. TRAIL Deletion Alters Macrophage Phenotype and Function
(A–C) (A) CCL-2 expression in basal macrophages. Inflammatory cytokine expression in macrophages in response to (B) LPS (20 ng/mL) challenge for 24 h or
(C) acLDL loading for 48 h followed by 16 h equilibration.
(D–G) (D) CD11b mRNA expression in basal macrophages and (E) flow cytometry analysis of CD11b+F4/80+ macrophages. Macrophage (F) cell counts after
7 days differentiation and (G) apoptosis determined by Annexin V staining after 7, 14, and 21 days differentiation.
(H and I) (H) MerTKmRNA expression and (I) efferocytosis in macrophages. Left, quantification. Right, representative images wheremacrophages are stained
blue, and apoptotic thymocytes are stained in green.
(J) Migration of macrophages to CCL-19, in a Transwell assay. n = 3/group. Results are mean G SEM. t-test; *p < 0.05.Apoe/ mice (Thorp et al., 2008). TRAILve macrophages also had significantly reduced migration to
CCL-19 (Figure 4J), a chemokine implicated in macrophage egress and plaque regression (Feig, 2014).
These findings suggest that macrophages lacking TRAIL may be defective in removing dead/dying cells
and modulating tissue repair.
TRAIL Deletion Effects the Nitric Oxide Synthase Pathway
The nitric oxide (NO) pathway is critical for maintenance of cardiovascular homeostasis and contributes
to maintaining an anti-thrombotic, anti-inflammatory, and anti-atherogenic state within the vessel wall.
Macrophages produce and respond to NO, and the inducible nitric oxide synthase (iNOS) pathway cata-
lyzes production of NO and citrulline from L-arginine. We focused on this because we reported that phys-
iologically relevant concentrations of TRAIL stimulate phosphorylation of endothelial-derived NOS (eNOS)
and increased intracellular NO concentrations in human endothelial cells, promoting their proliferation,
migration, and differentiation (Cartland et al., 2016; Di Bartolo et al., 2015). Plasma nitrate/nitrite levels
are an indicator of NO production in vivo. These were reduced in samples from HFD Trail/Apoe/
mice (Figure 5A). Furthermore, arginine and citrulline levels were significantly less in Trail/ plasma,
although levels of the endogenous NOS inhibitor, asymmetric dimethylarginine, remained unchanged
(Table 2). Plasma from BM-TRAIL mice also had significantly less citrulline compared with null- or paren-
chymal-TRAIL (Figure 5B), whereas plasma arginine levels were similar between groups (data not shown).
We also performed transcriptome analysis of aortic tissues from Trail/ and wildtype mice and found 845
genes were differentially expressed. Hierarchical clustering of these demonstrated opposing gene expres-
sion patterns, and gene ontology analysis indicated enrichment for biological processes (Figures 5C and
5D). Interestingly, cysteine/methionine metabolism was identified as a top pathway altered by TRAIL dele-
tion (enrichment score = 3.57; p = 0.028), and cysteine levels in plasma from these mice were 45% less
than in wildtype mice, whereas methionine concentrations did not change (Table 2). These findings are sig-
nificant because cysteine is important for NOS function (Forstermann and Sessa, 2012).46 iScience 12, 41–52, February 22, 2019
Figure 5. TRAIL Deletion Impairs NO Signaling
(A) Nitrate/nitrite in plasma from 12-week HFD Apoe/ and Trail/Apoe/ mice (n = 7–8/group).
(B) Citrulline levels in plasma from BMT mice. Metabolite peaks were quantified as area under the curve (n = 5–8/group).
(C and D) (C) Hierarchical clustering of 845 differentially expressed genes showing opposing gene expression patterns and (D) gene ontology (GO)
enrichment analysis. Analyses were performed as described in the Methods.
(E–J) (E) iNOS mRNA expression in TRAIL+ve vs. TRAILve macrophages, (F) after 20 ng/mL LPS stimulation for 24 h or (G) after acLDL loading for 48 h
followed by 16 h equilibration (n = 3). iNOS mRNA expression in aortic tissues from (H) 6-week wildtype vs. Trail/ mice (6–7/group), (I) 12-week HFD
Apoe/ vs. Trail/Apoe/, and (J) from null-, BM- and parenchymal-TRAIL mice (n = 5–6/group). mRNA expression was normalized to b-actin.
Results are mean G SEM. One-way ANOVA, t-test or Mann-Whitney U-test; *p < 0.05, **p < 0.01, ***p < 0.001, and p < 0.0001.iNOS is expressed by macrophages, and TRAILve macrophages had significantly less iNOS expression
constitutively, following LPS or acLDL stimulation (Figures 5E–5G). iNOS mRNA was40% less in aortic tis-
sue from Trail/ compared with wildtypemice (Figure 5H), and was reduced by90% in samples fromHFD
Trail/Apoe/ mice (Figure 5I). Importantly, iNOS mRNA in aortae from reconstituted BM-TRAIL mice
was restored when compared with null- and parenchymal-TRAIL samples (Figure 5J). Thus, TRAIL appears
integral to iNOS expression in macrophages and iNOShiTRAIL+ macrophages may help to maintain levels
of arginine and cysteine necessary to attenuate atherosclerosis.
IL-18 Negatively Regulates TRAIL Expression in Monocytes
We have identified an iNOShiTRAIL+ macrophage population that appears critical in moderating athero-
sclerosis. Mechanisms whereby TRAIL is reduced in monocytes from people with CAD are unknown. We
previously showed that patients with CAD had elevated plasma IL-18, IL-1b, and IL-6 concentrations (Mar-
tinez et al., 2015). Here, a significant inverse correlation between plasma TRAIL and IL-18 was observed in
these patient samples (R2 = 0.2344, p = 0.0105), but not between TRAIL and IL-1b, or IL-6 (Figure 6A), sug-
gesting an IL-18-TRAIL axis. In fact, IL-18mRNAwas significantly increased in aortic tissues from atheroscle-
rotic Trail/Apoe/mice (Figure 6B). To confirm a direct relationship, human monocytes were incubated
with recombinant IL-18 and TRAIL mRNA was measured. IL-18 significantly repressed TRAIL mRNA expres-
sion by60%, without affecting TNF-a (Figures 6C and 6D). We examined themechanism of this repression
further and measured the direct effect of IL-18 on NF-kB p65 and Sp1 expression, two transcription factors
that we showed control TRAIL transcriptional activity in vascular cells by combinatorial interaction (Chan
et al., 2010). IL-18 reduced NF-kB p65 mRNA expression in human monocytes by 50%, without affecting
Sp1 levels (Figures 6E and 6F). IL-18 also reduced NF-kB p65 activity, because the phosphorylated form (p-
NFkB p65) was significantly reduced, 50% (Figure 6G). NF-kB enrichment on the endogenous TRAILiScience 12, 41–52, February 22, 2019 47
Metabolite Wildtype Trail/
ADMA 0.4932G 0.1219 0.3556G 0.08856
Arginine 0.7568G .09599 0.5087G 0.04466**
Citrulline 0.1864G 0.0275 0.1483G 0.006803*
Cysteine 2.097G 0.1294 1.164G 0.1087**
Methionine 0.8381G .04502 0.7719G 0.1206
Table 2. Metabolomic Changes in 6-Week-Old Trail/ vs. Wildtype Plasma
ADMA, asymmetric dimethylarginine.
Metabolite peaks quantified as area under the curve. Results are meanG SD (n = 6); *p < 0.05, **p < 0.01.promoter was significantly reduced in healthy monocytes exposed to IL-18, whereas Sp1 enrichment re-
mained unaltered (Figure 6H). These findings indicate that IL-18 moderates TRAIL transcription by altering
NF-kB-binding activity. This mechanism may account for the reduced systemic TRAIL levels observed in
CAD.DISCUSSION
Despite aggressive risk factor management, many patients with CVD suffer heart attacks, highlighting the
need for new biomarkers, prognostic factors, and therapies. Here, we have identified that monocytes from
healthy human donors are a significant source of TRAIL, whereas monocytes from patients with CAD ex-
press significantly less TRAIL mRNA, concomitant with reduced plasma levels. In mice with severe disease,
reconstitution of TRAIL+ monocyte/macrophages markedly attenuated atherosclerosis by reducing macro-
phage accumulation and increasing iNOS levels. Furthermore, we identified IL-18 as a negative regulator of
TRAIL transcription in human monocytes. The recent identification of TRAIL SNPs associating with athero-
sclerosis (Pott et al., 2017) further underpins the biological significance of our findings. Circulating TRAIL
levels, and/or TRAIL/IL-18 ratios, may predict an individual’s risk of developing CVD. Our work also high-
lights the potential for targeting monocyte/macrophage-derived TRAIL in atherogenesis for the treatment
of CVD.
Much of TRAIL biology has focused on its ability to kill cancer cells. However, low TRAIL concentrations
positively associate with CVD in people (Schoppet et al., 2006), suggesting a role that goes beyond that
of killing. Indeed, non-apoptotic functions, including stimulation of cell survival, proliferation, and
migration, particularly in vascular cells (Azahri et al., 2012; Cartland et al., 2014, 2017; Chan et al.,
2010; Di Bartolo et al., 2015; Harith et al., 2015; Kavurma et al., 2008a; Secchiero et al., 2004a,
2004b), and even cancer cells, (Lancaster et al., 2003; Secchiero et al., 2005) have been described.
However, in CVD, because TRAIL’s cellular source is unknown, the reason why concentrations were
reduced and the direct impact this could have on pathogenesis were unclear. Here we show that
monocyte/macrophages represent a significant source of TRAIL in healthy individuals, which was
suppressed in monocytes from patients with CAD. We identified IL-18 as a negative regulator of
TRAIL expression in these cells. IL-18 is synthesized as an inactive precursor, expressed constitutively
by macrophages and other cells within the vessel wall (Gerdes et al., 2002; Gracie et al., 2003).
This has significant implications because circulating IL-18 levels are increased in patients with CAD
(Martinez et al., 2015; Robertson et al., 2016) and IL-18 is linked to atherosclerosis in mice (Elhage
et al., 2003; Whitman et al., 2002), with mature IL-18 secreted primarily from monocyte/macrophages
following caspase-1 cleavage (Gerdes et al., 2002; Gracie et al., 2003). IL-18 can also modulate activity
of multiple transcription factors, including NF-kB and Sp1 (Reddy et al., 2010), and critically, we showed
that IL-18 influenced NF-kB binding ability on the endogenous TRAIL promoter, contributing to sup-
pressed TRAIL transcription. These suggest a mechanism for reduced TRAIL levels observed in patients
with CAD.
NO is a powerful vasodilator and plays important roles in inflammation and maintaining vessel tone
(MacMicking et al., 1997). iNOS is generally expressed by proinflammatory macrophages in atherosclerosis
(Moore et al., 2013). We found markedly less iNOS mRNA in Trail/Apoe/macrophages and in vascular
tissue from Trail/ and Trail/Apoe/ mice, particularly from the latter that were fed a HFD and48 iScience 12, 41–52, February 22, 2019
Figure 6. IL-18 Represses TRAIL Expression in Monocytes
(A) Spearman’s correlation between plasma TRAIL and IL-18, IL-1b, and IL-6.
(B) Aortic IL-18 mRNA expression in 12-week HFD Apoe/ and Trail/Apoe/ (n = 5–7). (C–F) Monocytes were isolated from healthy human donors and
treated with recombinant human IL-18 (30 ng/mL) for 24 h followed by assessment of (C) TRAIL, (D) TNF-a, (E) NF-kB p65, and (F) Sp1 mRNA expression
measured by qPCR (n = 3).
(G) IL-18 (30 ng/mL) represses NF-kB p-p65 protein expression in human monocytes as assessed by western blotting, quantification on right (n = 3). (H) IL-18
(30 ng/mL) reduces NF-kB enrichment on the endogenous TRAIL promoter, but Sp1 enrichment remained unaltered.
Results are mean G SEM. One-way ANOVA or t-test; *p < 0.05 and **p < 0.01.manifested a strong atherosclerotic phenotype. Reconstitution of Trail/Apoe/mice with bone marrow
expressing TRAIL markedly increased aortic iNOS mRNA, and concentrations of its metabolite citrulline
were significantly less than in null- or parenchymal-TRAIL expressing samples. Thus, TRAIL+ monocyte/
macrophages may contribute to vascular protection by increasing iNOS gene expression, thereby facili-
tating NOproduction. Our findings, and those of Lu et al. (2015), challenge the concept of iNOS as amarker
of inflammatory macrophages. For example, macrophages from iNOS/mice showed increased polariza-
tion to an inflammatory macrophage (Lu et al., 2015), and NO generated by iNOS reduced leukocyte-endo-
thelium interactions (Hickey et al., 1997). IL-18 also modulates iNOS via NF-kB-dependent mechanisms (Ja-
blonska et al., 2006); however, an interesting control mechanism worthy of consideration in this context is
the prevention of IL-18 release from macrophages by NO-mediated suppression of caspase-1 (Kim et al.,
2002). Taken together, our findings suggest that TRAIL regulates the iNOS pathway in macrophages, and it
is tantalizing to speculate that TRAIL-induced iNOS attenuates their infiltration via NO to reduce athero-
genesis. Notably, these may also be influenced by IL-18.
In chronic CVD, macrophages change from a resolving to a pro-inflammatory phenotype, propagating the
inflammatory milieu of the plaque (reviewed in Kavurma et al., 2017). Here we propose TRAIL as a player in
macrophage biology, protecting against atherosclerosis and macrophage accumulation, and provide
mechanistic insights into monocyte/macrophage function(s) in CAD. We propose that the reduced TRAIL
expression in monocyte/macrophages from patients with CAD may impair these processes, i.e., by
promoting amore inflammatory monocyte/macrophage, increasing cellular cholesterol accumulation in le-
sions, aggravated by the inability of these cells to egress, or efferocytose, which collectively result in severeiScience 12, 41–52, February 22, 2019 49
atherosclerosis. Interestingly, TRAIL+ monocyte/macrophage reconstitution also reduced inflammation in
pancreata. Thus, impairment of macrophage processes as observed in atheroma may also be evident in
pancreatic islets. Indeed, during islet inflammation, proinflammatory macrophages contribute to b-cell
dysfunction in diabetes, yet resolving macrophages are essential for physiological b-cell proliferation
and survival (Eguchi and Nagai, 2017). Whether TRAIL’s pro-resolving function(s) in macrophages affect
b-cell function is unclear. Interestingly, however, TRAIL+ parenchymal cells also inhibited MAC3+ cell accu-
mulation to the same degree as reconstitution of TRAIL+ monocyte/macrophages. TRAIL-expressing
parenchymal cells also improved whole-body glucose clearance in response to a glucose tolerance test.
These findings suggest two things: that whenmonocyte/macrophage accumulation is the driver of disease,
as in atherosclerosis, TRAIL+ monocyte macrophages are critical in reducing inflammation and disease.
However, when monocyte/macrophage accumulation may not be the primary driver of disease, such as
in diabetes, TRAIL-expressing parenchymal cells play a more prominent role in protection, suggesting a
tissue/cell-specific role. These findings are significant as they provide important information on which tis-
sue/cells to target in the treatment of atherosclerosis vs. metabolic diseases dependent on TRAIL
signaling.
In summary, we have identified a unique population of iNOShiTRAIL+ monocyte/macrophages, and these
appear to be potent suppressors of inflammation and atherosclerosis. Furthermore, we suggest TRAIL is a
key modulator of macrophage phenotype and function. Our findings are important because TRAIL expres-
sion is low in monocytes from people with CAD, concomitant with high IL-18 and low TRAIL concentrations
in plasma. These studies highlight an exciting immunotherapeutic potential in the treatment of atheroscle-
rosis. Results may spawn wider interest in the role of this macrophage phenotype in chronic inflammatory
conditions.
LIMITATIONS OF THE STUDY
Atherosclerosis is a multifactorial disease involving other immune cells or their interactions. The study
design did not investigate the effect of TRAIL on other bone-marrow-originating cells, including neutro-
phils, T cells, and B cells, implicated in plaque progression or their interaction with monocyte/macro-
phages. Furthermore, our investigations into the cause of TRAIL suppression focused only on IL-18, yet
owing to the complex nature of atherosclerosis, other factors are also likely to contribute.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, two figures, and three tables and can be found
with this article online at https://doi.org/10.1016/j.isci.2018.12.037.
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Figure S2. TRAIL deletion does not affect hematopoietic stem cell numbers. Percentage of progenitor cells in bone marrow of 6 w Trail-/-Apoe-/- (TRAIL-ve) and
Apoe-/- (TRAIL+ve) mice is not significantly different (n=5/genotype). Results are Mean±SEM.
SUPPLEMENTARY TABLES 
 
Table S1. Details of control, stable and unstable CAD patients. Related to Figures 1 and 6. 
(Martinez et al., 2015) 
 
Patient Characteristics 
Control             
n=8 
Stable CAD 
n=15 
Unstable 
CAD n=12 
Age (y) Mean (SD) 59.3 (5.7) 63.1 (9.3) 64.4 (11.6) 
Female (%) 1 (13) 1 (7) 0 (0) 
Diabetes mellitus (%) 1 (14) 4 (27) 3 (25) 
Hypertension (%) 2 (29) 7 (47) 8 (67) 
Dyslipidaemia (%) 3 (43) 9 (60) 10 (83) 
Family history (%) 0 (0) 4 (27) 2 (17) 
Current smoker (%) 3 (43) 4 (27) 3 (25) 
Previous MI (%) 1 (13) 4 (27) 2 (17) 
Previous PCI (%) 1 (13) 6 (40) 1 (8) 
Previous CABG (%) 0 (0) 3 (20) 1 (8) 
Renal impairment (%) 0 (0) 2 (13) 2 (17) 
 
PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass 
graft. 
 
  
Table S2. Details of CAD patients (2nd cohort). Related to Figure 1. (Robertson et al., 2016) 
 
Patient Characteristics (n=11)  
Age (y) Mean (SD) 67.55 (14.57)  
Female (%) 3 (27)  
Diabetes mellitus (%) 4 (36)  
Hypertension (%) 10 (91)  
Dyslipidaemia (%) 8 (73)  
Family history (%) 5 (46)  
Current smoker (%) 3 (27)  
Previous MI (%) 6 (55)  
Previous PCI (%) 3 (27)  
Previous CABG (%) 3 (27)  
Renal impairment (%) 3 (27)  
 
PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass 
graft. 
 
 
  
Table S3. Primer sequences. Related to Figures 1-6. 
 
Human 5’-3’ 
 Forward Reverse 
TRAIL ACCAACGAGCTGAAGCAGAT CAAGTGCAAGTTGCTCAGGA 
TNF- GTTGTAGCAAACCCTCAAGCTG GAGGTACAGGCCCTCTGATG 
NFB p65 GGTCCACGGCGGACCGGT GACCCCGAGAACGTGGTGCGC 
Sp1 CCATACCCCTTAACCCCG GAATTTTCACTAATGTTTCCCACC 
GAPDH GAAGGCTGGGGCTCATTT CAGGAGGCATTGCTGATGAT 
   
Murine 5’-3’ 
 Forward Reverse 
ABCA1 AAAACCGCAGACATCCTTCAG CATACCGAAACTCGTTCACCC 
ABCG1 CGAGAGGGCATGTGTGACG CCGAGAAGCTATGGCAACC 
CCL2 GCTGGAGCATCCACGTGTT ATCTTGCTGGTGAATGAGTAGCA 
CD11b ATGGACGCTGATGGAATACC TCCCCATTCACGTCTCCCA 
CD36 AGATGACGTGGCAAAGAACAG CCTTGGCTAGATAACGAACTCTG 
F4/80 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
IL-10 GCTGGACAACATACTGCTAACC ATTTCCGATAAGGCTTGGCAA 
IL-18 GACTCTTGCGTCAACTTCAAGG CAGGCTGTCTTTTGTCAACGA 
IL-1β GTTTCTGCTTTCACCACTCCA GAGTCCAATTTACTCCAGGTCAG 
IL-6 CTGCAAGAGACTTCCATCCAG AGTGGTATAGACAGGTCTGTTGG 
iNOS CGAAACGCTTCACTTCCAA TGAGCCTATATTGCTGTGGCT 
MerTK CTCCTGAGCCCGTCAATATCT AGACCAGGTACGGTTAGGACA 
SRA GGCAATGACTTTGGTACACAGT TGGTGGTAGTCTTCGGCATAG 
SRB1 TTTGGAGTGGTAGTAAAAAGGGC TGACATCAGGGACTCAGAGTAG 
TNF-α CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 
TRAIL CAGGCTGTGTCTGTGGCTGT TGAGAAGCAAGCTAGTCCAATTTTG 
β-Actin AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA 
 
  
TRANSPARENT METHODS 
Patient studies- Patients presenting for cardiac catheterization at The Royal Prince Alfred Hospital, 
Sydney Australia, and previously recruited by us were used: (i) control (ii) stable and (iii) unstable CAD 
(Table S1). The control group were deemed to have no significant coronary disease as identified during 
angiography (Martinez et al., 2015). Blood was drawn from the aortic root, right atrium and coronary 
sinus prior to the procedure (Martinez et al., 2015). A second cohort of patients presenting with unstable 
CAD (n=11) had peripheral venous blood drawn within 24 h of admission. Venous blood from 7 healthy 
individuals served as controls. Patient details as previously reported are listed in Table S2 (Robertson 
et al., 2016). All procedures were conducted in accordance with the Sydney Local Health District 
Human Ethics Committee (X12-0241; Sydney, Australia) and all patients gave written informed 
consent before participating.  
Human ELISAs –TRAIL and TNF-α in blood plasma were quantified according to the manufacturer’s 
instructions (R&D Systems Inc.). 
Human monocyte isolation – Peripheral blood mononuclear cells (PBMC) isolated as described 
(Robertson et al., 2016), were suspended in DMEM (Gibco) supplemented with 5% fetal bovine serum 
(FBS). PBMC (8×104/well) were seeded onto 48-well plates (Corning) and non-adherent leukocytes 
removed 1 h later. Buffy coats (Australian Red Cross Blood Service) were used for IL-18 treatments. 
Isolated white cells were separated, and fractions examined using Wrights’ stain (DiffQuik; Laboratory-
Aids) (Ravindran et al., 2017). Monocytes were resuspended in serum-free RPMI 1640 (Gibco) 
containing penicillin (10 µg/ml), streptomycin (10 μg/ml), and L-glutamine (2 mM), and within 3 h of 
plating, cells were exposed to 10% human serum and recombinant IL-18 (30 ng/ml; R&D Systems) for 
24 h at 37° C in a humidified atmosphere of 5% CO2. All procedures were conducted in accordance 
with the Sydney Local Health District Human Ethics Committee (Reference X9.5/JUL17; Sydney, 
Australia).  
Animal studies – Trail-/-Apoe-/-, Apoe-/- and Trail-/- and wildtype littermate control mice are described 
by us (Cartland et al., 2017; Di Bartolo et al., 2011), bred at Australian BioResources (NSW, Australia) 
and backcrossed 6 generations since 2013 and 2014, and at least 10 generations prior to 2007 (Cartland 
et al., 2017; Di Bartolo et al., 2011). C57Bl6/J (wildtype; IMSR_JAX:000664) mice were purchased 
from Australian Resources Centre (WA, Australia) or Australian BioResources. For studies involving 
a “Western” high fat diet (HFD; Specialty feeds; WA, Australia), 6 w old mice were placed on the diet 
for up to 12 w (Di Bartolo et al., 2011). After an overnight fast, mice were anaesthetized by i.p. injection 
of ketamine (100 mg/kg) and xylazine (10 mg/kg), or by inhalation of 2% isoflurane prior to euthanasia 
by cardiac exsanguination. Plasma isolated from blood was snap-frozen and stored at -80°C. Indicated 
tissues were collected for gene expression or immunohistochemistry (IHC). Protocols were approved 
by the Animal Care and Ethics Committee at University of New South Wales (08/105A; 11/54B) or the 
Sydney Local Health District Animal Ethics Committee (2014-014; 2013-049) (Sydney, Australia). 
Bone marrow chimeras – 8 w old male Trail-/-Apoe-/- and Apoe-/- mice were given a lethal dose of 
radiation (8-9 Gys), randomized, transplanted with 107 bone marrow cells from Trail-/-Apoe-/- or Apoe-
/- mice 24 h later (Figure 2a), and given 4 w for chimerization as described by us (Stoneman et al., 2007; 
Yu et al., 2011; Zhao et al., 2010). Mice were then fed a HFD for 12 w and euthanized as above. 
Macrophage depletion - 6 w old male Trail-/-Apoe-/- mice were placed on a HFD for 12 w. After 1 w, 
mice were randomized, given weekly i.p. injections of liposomes containing clodronate (15 mg/kg), or 
control PBS (both from Clodronateliposomes.com), then euthanized as above. 
Glucose and insulin tolerance tests (GTT, ITT) - were performed 10 and 11 w into the HFD (Cartland 
et al., 2014). 
Murine plasma chemistries - Plasma glucose was measured using a glucometer (Accu-check Performa, 
Roche). Insulin (Mercodia), cholesterol, triglycerides (all from Wako Diagnostics) and TRAIL (USCN 
Life Science Inc.) were assessed according to the manufacturer’s instructions. 
Histology – Brachiocephalic artery (3 m) and pancreata sections (5 m) were stained with H&E to 
assess plaque or islet size. IHC was performed using anti-Mac3 (1:100, BD Biosciences) for 
macrophage infiltration and anti-caspase 3 to measure apoptosis (1:200, R&D Systems) (Di Bartolo et 
al., 2011). Immunofluorescence was performed on sections of pancreata using guinea pig anti-insulin 
(1:1000, Dako), and detected with anti-guinea pig Alexa 488 (1:500, ThermoFisher). All control 
sections with primary antibody omitted were negative. Images were captured using an Olympus BX53, 
Zeiss Axio Imager Z2 or Zeiss Axio Scan.Z1 microscope. Plaque and islet size were measured using 
ImageJ and percent of positive staining/tissue image area quantified using Image-Pro Premier 
(Cybernetics); 20-30 islets/mouse were assessed (Di Bartolo et al., 2011). 
Total RNA isolation, cDNA and quantitative PCR (qPCR) – RNA was isolated from human monocytes 
and bone marrow-derived macrophages using the RNeasy Isolation Kit (QIAGEN) or TRI Reagent 
(Sigma), and from homogenized aortic tissue, using the RNeasy Fibrous Tissue Mini Kit (QIAGEN) 
(Cartland et al., 2017; Robertson et al., 2016). RNA was reverse transcribed using the iScript cDNA 
synthesis kit (BioRad, Australia). Real-time PCR was performed using iQ SYBR in a CFX384 
thermocycler (BioRad, Australia). Relative changes in mRNA expression were determined using the 2-
∆∆cT method normalized to housekeeping genes GAPDH or -actin. Human and murine primer 
sequences are in Table S3. 
Mouse macrophages – Bone marrow flushed from femurs and tibias of Trail-/-Apoe-/- and Apoe-/- mice, 
were incubated in RPMI 1640 supplemented with 10% (v/v) heat-inactivated foetal calf serum (HIFCS), 
50 IU/ml penicillin G, 50 μg/ml streptomycin, 2 mM glutamine with 10 mM HEPES, and 20% (v/v) L-
cell conditioned medium as a source of M-CSF (Du et al., 2015). Macrophages were considered fully 
differentiated after 7 days; viability was determined by Trypan blue exclusion. Phagocytosis assay – 
Macrophages in RPMI 1640 supplemented with 50 IU/ml penicillin G, 50 μg/ml streptomycin, 2 mM 
glutamine with 10 mM HEPES, were serum-starved overnight. Phagocytosis was assessed the following 
day using the Phagocytosis Assay Kit (Caymen Chemical) according to manufacturer’s instructions. 
Analysis was performed using a BD FACSVerse flow cytometer as above. 
Cholesterol loading and efflux – For cholesterol loading studies, macrophages at 5 x 105 per well in a 
12 wtp were incubated in complete medium containing 25 µM acLDL for 48 h, followed by 2X PBS 
washes and 16 h equilibration in RPMI containing 1% FBS. Cells were washed 2X in PBS prior to 
harvest or efflux. For efflux studies, acLDL was incubated with 3H-cholesterol overnight at 4°C and 
then added to complete medium at 2µCi/25 µg acLDL, and cells treated as above. Efflux was induced 
by incubating cells in RPMI containing 0.1% BSA (fatty acid free; Sigma Aldrich) ApoA1(5 µg/ml) 
for 4 h. 3H was counted by liquid scintillation for radioactivity in media and cells, and efflux calculated 
as (counts in media/counts in media and cells) (Du et al., 2015). 
Flow cytometry – Bone marrow harvested from femurs and tibias underwent brief red blood cell lysis, 
resuspended in HBSS and incubated with a cocktail of antibodies that react with lineage-committed 
cells and stem cell markers as described by us (Murphy et al., 2011). Analysis was performed on a BD 
FACS CantoII flow cytometer. Macrophages were harvested and counted, blocked in PBS containing 
5% heat inactivated normal rabbit serum, 0.5% BSA, 2 mM NaN3 and mouse FcR blocking reagent 
(Milteyni Biotec Australia Pty. Ltd.), washed in PBS containing 1% HIFCS and 2 mM NaN3 and 
incubated with antibodies to CD11b-BV510 and F4/80-BV421 (BD Biosciences). Flow cytometry was 
performed using a BD FACSVerse and analyzed using FCS Express (De Novo Software). 
Apoptosis assay - macrophages were differentiated for 7, 14, or 21 days. Cells were stained with 
Annexin V (Invitrogen) according to manufacturer’s instructions and analyzed by flow cytometry 
within 1 h. Results expressed as annexin V staining as a percentage of the total cell population. 
Efferocytosis assay – Macrophages were seeded onto glass coverslips. Apoptotic thymocytes (treated 
with 5 µM dexamethasone for 12 h; ~95% Annexin V positive) were stained with CFSE (Invitrogen), 
as per manufacturers protocol and added 1:10 (macrophage:thymocyte). Co-cultures were incubated for 
2 h, and then thoroughly washed to remove non-efferocytosed cells. Cells were fixed in 10% neutral 
buffered formalin, and macrophages were stained with F4/80-BV421 (BD Biosciences). 3-9 images 
were taken on a Zeiss Axio Imager Z2 microscope. Efferocytic index was quantified as the number of 
macrophages that contained thymocytes as a ratio of total macrophages in the image (Khanna et al., 
2010).  
Migration assay – Macrophages (106 in 100 μl) were plated onto 5 μm transwell filters (Costar), 
incubated for 2 h in RPMI 1640 then filter inserts transferred to wells containing 600 μl recombinant 
murine CCL-19 (0.1 μg/ml; R&D Systems), and incubated at 37°C for 24 h. Cells that had migrated 
through the filter were counted manually. 
 
Metabolomic Profiling - Deproteinized plasma extracts from 6 w old Trail-/- and wildtype, and bone 
marrow chimera mice were subjected to normal phase hydrophilic interaction chromatography 
(Kimberly et al., 2017). Metabolite peaks were integrated using Sciex MultiQuant software. All 
metabolite peaks were manually reviewed for peak quality in a blinded manner. In addition, pooled 
cellular extract samples were interspersed within each analytical run at standardized intervals every 10 
injections, enabling the monitoring and correction for temporal drift in mass spectrometry performance. 
The nearest neighbor flanking pair of pooled plasma was used to normalize samples in a metabolite-by-
metabolite manner. Internal standard peak areas were monitored for quality control and individual 
samples with peak areas differing from the group mean by >2 standard deviations were reanalyzed. 
Transcriptome profiling - Total RNA from aortae of 6 w old Trail-/- and C57Bl6/J wildtype mice (n=3) 
was interrogated using Affymetrix MoGene 1.0 ST v1.0 gene arrays according to Ramaciotti Centre for 
Genomics (University of New South Wales, Australia). This data has been deposited in 
Gene Expression Omnibus GEO DataSets:GSE107645. Interrogating probes were normalized 
using a robust multi-array average (RMA) algorithm and RMA background corrected (Partek 
Genome Suite, Partek). Quantile normalization and median polish was used for probeset 
summarization, in log 2 space. Principle Component Analysis was used to identify distinct gene 
expression between the two groups. One-way ANOVA of Trail-/- vs. wildtype, with unadjusted 
p<0.05, identified differentially expressed genes. Post-hoc analysis i.e. false discovery rate was 
considered but was too stringent and biologically significant genes were filtered out as described (Ng 
et al., 2010). Thus, differentially expressed genes (at unadjusted P<0.05) were used for further 
analysis. Hierarchical clustering of differentially expressed genes was performed by complete linkage 
using Euclidean distance as a similarity metric to identify co-regulated or functionally-related 
genes affected by TRAIL deletion. Gene Set Enrichment Analysis according to Gene Ontology 
(GO) was used to identify specifically enriched regulatory pathways affected by TRAIL deletion. 
Western blotting – Cells were lysed in RIPA buffer. Proteins were resolved on Bolt 4-12% Bis-Tris 
Plus Gels (Invitrogen, Australia) and transferred onto a nitrocellulose membrane (iBlot 2 Transfer 
Stacks; Invitrogen, Australia). Membranes were blocked with 5% skim milk, followed by incubation 
with primary antibodies; β-actin (15 min, 1:30000, Sigma); nuclear factor-kappa B (NFκB) p65 was 
detected using a mouse monoclonal antibody (overnight, 1:1000, Abcam) and phosphorylated NFκB 
p65 (p-NFκB p65, overnight, 1:1000, Abcam). Horseradish peroxidase-conjugated secondary 
antibodies (Dako) were used and signal detected by chemiluminescence (ECLTM, Western blotting 
detection reagent, GE Healthcare, Chalfont St Giles, Buckinghamshire, UK) 
Chromatin immunoprecipitation (ChIP) – performed as previously described (Chan et al., 2010) using 
human monocytes treated with 30 ng/ml IL-18 overnight. The immunoprecipitation step was performed 
using 0.5 µg NFB (Abcam) or rabbit IgG (Millipore). The human TRAIL promoter was amplified 
using primer sequences that amplify the NFB site (Chan et al., 2010): 5’-
GGAGAGCAAGAAAGAGAAGAGAGA-3’ (forward), 5’- GTGAGGAAATGAAAGCGAATG-3’ 
(reverse) using SYBER green with cycling conditions 95 ˚C for 10 min, followed by 40 cycles at: 95˚C 
10 sec, 60˚C 15 sec and 72˚C 20 sec.  
Statistics – Unless indicated, all results were expressed as means ± S.E.M. Statistical comparisons were 
made using Students t-tests, Mann-Whitney U-tests or one- or two-way ANOVA, with Bonferroni’s 
post-test where appropriate. Analysis was performed in GraphPad Prism Version 7.0 (GraphPad 
Software). A value of p<0.05 was considered significant. Where necessary, statistical outliers were 
excluded using the Grubb’s test.  
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